PSE
27.4.2021 16:36:05 CEST | Business Wire | Press release
Process Systems Enterprise (PSE), A Siemens Business, today announced the full release of gPROMS FormulatedProducts 2.0, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005797/en/
The release at the 2021 Advanced Process Modelling Forum follows an early release to key customers, and reflects the substantial investment Siemens is making into PSE’s product development to provide the process industries with a new generation of digital tools.
Version 2.0 introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 7.0, such as surrogate modelling. Additions include new mechanistic model libraries for developing bioprocess digital twins of bioreactor, membrane filtration and chromatography processes, and a new mechanistic canine model for the design, virtual formulation prototyping and risk analysis of clinical and pre-clinical drug product formulations.
Version 2.0 also introduces key library enhancements in active ingredient manufacture, formulation manufacture and product performance. Workflows when specifying buffers and media compositions of in vitro vessel, solution and suspension dosage forms have been streamlined, and equilibrium limited reactions added to the chemical synthesis libraries. Additionally, this release includes many usability and robustness enhancements to provide an improved user experience, such as a new case file structure, streamlined data import workflows using a new experiment data manager, parallel multi-start optimization and parameter estimation, and new cross-disciplinary examples and templates that can directly be customised to users’ projects.
Sean Bermingham, VP Formulated Products at PSE, says: “We are working closely with our major users in pharma, F&B, FMCG, specialty chemicals and mining, with their requirements driving our extensive development programme. Our focus is now in extending usability and the ability to embed gPROMS FormulatedProducts in organisations’ workflows to open the application of sophisticated digital design approaches to a wider range of users, and the Siemens investments are allowing us to move forward rapidly.”
PSE continues to lead innovation in advanced process modelling capabilities for the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors through the support of industrial & academic partners, funded development projects such as NextGen DDaMM, D-DAP, DIDCOM-FP, and the Systems-based Pharmaceutics Alliance.
For editors
‘About’: www.psenterprise.com/news
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005797/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom